Granuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathways - 19/06/20
Abstract |
Background |
Granuloma annulare (GA) is an inflammatory skin disorder. Localized GA is often self-resolving, but generalized GA is often recalcitrant to treatments. There are no targeted treatments for GA, largely due to lack of mechanistic understanding. Recently, tumor necrosis factor antagonism showed promise in GA, suggesting an underlying immune pathogenesis.
Objective |
To elucidate the immune pathogenesis and identify potential therapeutic targets for GA.
Methods |
Lesional and nonlesional skin biopsy samples were obtained from patients with GA and evaluated for a large array of inflammatory markers compared with inflammatory markers from normal skin of healthy individuals.
Results |
We found differential expression of many inflammatory genes compared with normal skin. These genes were associated with T-helper (Th) cell type 1/innate immunity (tumor necrosis factor-α, interleukin [IL]-1β, IL-12/23p40, signal transducer and activator of transcription 1, chemokine [C-X-C motif] ligand 9/10), Janus kinase signaling, and Th2 (IL-4, IL-31, chemokine (C-C motif) ligands 17 and 18; P < .05). Unexpectedly, IL-4 showed significant upregulation in GA lesional skin vs control skin (15,600-fold change).
Limitations |
Limited sample size.
Conclusions |
Our findings shed light on the inflammatory pathways of GA, supporting the notion that immune mechanisms could be driving disease, as suggested by the promising data of tumor necrosis factor-α inhibitors in GA. The significant Janus kinase and particularly Th2 signaling in GA advocates for the investigation of specific Janus kinase- and Th2- targeted drug therapy.
Le texte complet de cet article est disponible en PDF.Graphical abstract |
Key words : dermatology, granuloma annulare, immunology, pathogenesis
Abbreviations used : AD, CAMP, CCL, CXCL, FCH, GA, IFN-γ, IL, JAK, KRT16, MMP, mRNA, OSM, RT-PCR, STAT, SYK, Th, TNF-α, TYK
Plan
| Authors Min and Wu contributed equally to this article as cofirst authors. |
|
| Funding sources: None. |
|
| Conflicts of interest: Drs Zhang and Pavel are employees of Mount Sinai. Dr Lebwohl is an employee of Mount Sinai, which receives research funds from Amgen Inc, Anacor Pharmaceuticals, Inc, Boehringer Ingelheim, Celgene Corporation, Eli Lilly & Co, Janssen Biotech, Kadmon Corporation, LLC, LEO Pharma, MedImmune, LLC, Novartis AG, Pfizer Inc, Sun Pharmaceutical Industries Inc, and Valeant Pharmaceuticals North America LLC. Dr Guttman-Yassky is an employee of Mount Sinai and has received research funds (grants paid to the institution) from AbbVie, Celgene, Eli Lilly, Janssen, MedImmune, AstraZeneca, Novartis, Pfizer, Regeneron, Vitae, Glenmark, Galderma, Asana, Innovaderm, Dermira, and UCB, and is also a consultant for Sanofi, Regeneron, Stiefel/GlaxoSmithKline, MedImmune, Celgene, Anacor, AnaptysBio, Dermira, Galderma, Glenmark, Novartis, Pfizer, Vitae, LEO Pharma, AbbVie, Eli Lilly, Kyowa, Mitsubishi Tanabe, Asana Biosciences, and Promius. Authors Min, Wu, He, Sanz-Cabanillas, Del Duca, and Renert-Yuval have no conflicts of interest to disclose. |
|
| Reprints not available from the authors. |
|
| IRB approval status: Reviewed and approved by the Mount Sinai Institutional Review Board (approval HS #14-00436.) |
Vol 83 - N° 1
P. 63-70 - juillet 2020 Retour au numéro
Article précédent
- Pathophysiologic mechanisms of itch in bullous pemphigoid
- Takashi Hashimoto, Christina Dorothy Kursewicz, Rachel Alison Fayne, Sonali Nanda, Serena Maya Shah, Leigh Nattkemper, Hiroo Yokozeki, Gil Yosipovitch
- Histologic comparison of tumor necrosis factor-? inhibitor–induced psoriasis and psoriasis vulgaris
- Jeffrey Zhu Hu, Steven D. Billings, Di Yan, Anthony Patrick Fernandez
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?